FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FFI FUND LTD		 2. Issuer Name and Ticker or Trading Symbol

Clarus Therapeutics Holdings, Inc. [ CRXT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O BRACEBRIDGE CAPITAL, LLC, 888 BOYLSTON STREET, 15TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

9/17/2021
(Street)

BOSTON, MA 02199
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/17/2021  S  127360 (1)D$9.20 (2)2102495 I See footnote (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Shares of common stock, $0.0001 par value per share ("Shares") of Clarus Therapeutics Holdings, Inc. (the "Issuer"), were sold as follows: (i) 92,973 Shares were sold by FFI Fund Ltd. ("FFI"), (ii) 17,830 Shares were sold by FYI Ltd. ("FYI"), and (iii) 16,557 Shares were sold by Olifant Fund, Ltd. (together with FFI and FYI, the "Bracebridge Funds"). Bracebridge Capital, LLC (the "Investment Manager") is the investment manager of each of the Bracebridge Funds and has the authority to vote and dispose of all the Shares reflected herein.
(2) This price is a weighted-average price. These Shares were sold in multiple transactions at prices ranging from $9.05 to $9.34, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the ranges set forth in this explanatory note.
(3) Each of the Bracebridge Funds and the Investment Manager disclaims beneficial ownership of the Shares except to the extent of any pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the Shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
FFI FUND LTD
C/O BRACEBRIDGE CAPITAL, LLC
888 BOYLSTON STREET, 15TH FLOOR
BOSTON, MA 02199
X

FYI Ltd
C/O BRACEBRIDGE CAPITAL, LLC
888 BOYLSTON STREET, 15TH FLOOR
BOSTON, MA 02199
X

Olifant Fund, Ltd.
C/O BRACEBRIDGE CAPITAL, LLC
888 BOYLSTON STREET, 15TH FLOOR
BOSTON, MA 02199
X

Bracebridge Capital, LLC
888 BOYLSTON STREET, 15TH FLOOR
BOSTON, MA 02199
X
Signatures
/s/ FFI Fund Ltd., By Nancy Zimmerman, Authorized Representative9/21/2021
**Signature of Reporting PersonDate

/s/ FYI Ltd., By Nancy Zimmerman, Authorized Representative9/21/2021
**Signature of Reporting PersonDate

/s/ Olifant Fund, Ltd., By Nancy Zimmerman, Authorized Representative9/21/2021
**Signature of Reporting PersonDate

/s/ Bracebridge Capital, LLC, By Nancy Zimmerman, Authorized Representative9/21/2021
**Signature of Reporting PersonDate
Clarus Therapeutics (NASDAQ:CRXT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Clarus Therapeutics Charts.
Clarus Therapeutics (NASDAQ:CRXT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Clarus Therapeutics Charts.